Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
One Call acquisition of Data Dimensions
We are advising One Call on the transaction
Tandem Diabetes Care $300 million convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
Revolution Medicines $1 billion at-the-market offering
We advised the sales agent on the offering
Recursion Pharmaceuticals $300 million at-the-market offering
We advised the sales agent on the offering
Amgen $4 billion notes offering
We advised the bookrunners on the offering
Coloplast acquisition of Uromedica
We are advising Coloplast on the transaction
BioMarin Pharmaceutical $850 million debut senior notes offering
We advised the representative of the initial purchasers
Coherus Oncology $50 million follow-on offering
We advised the joint book-running managers and representatives of the underwriters on the offering
Rhône Capital acquisition of Invacare
We advised Highbridge Capital, as an Invacare secured lender and noteholder, on the transaction
Ascletis Pharma HK$843.5 million placement of shares
We advised the placing agent on the transaction